Sign Out
Effects of Other Medicinal Products on the Pharmacokinetics of ENHERTU: Coadministration with ritonavir, a dual inhibitor of OATP1B/CYP3A, or with itraconazole, a strong CYP3A inhibitor, resulted in no clinically meaningful increase in exposures of ENHERTU or the released topoisomerase I inhibitor. No dose adjustment is required during coadministration of ENHERTU with drugs that are inhibitors of OATP1B or CYP3A.
No clinically meaningful interaction is expected with drugs that are inhibitors of P-glycoprotein (P-gp), MATE2-K, MRP1, or BCRP transporters.
Effects of ENHERTU on the Pharmacokinetics of Other Medicinal Products: In vitro studies indicate that the topoisomerase I inhibitor component of ENHERTU does not inhibit or induce major CYP450 enzymes.
